PIPELINE
A disciplined, criteria-driven pipeline
AllianceXPartners is actively screening and diligencing candidate programs against a consistent set of criteria. Because discussions with specific companies are confidential until a deal is signed, we describe the pipeline by profile rather than by name.
Screening criteria
Failed, not fatal
A completed late stage clinical or equivalent pivotal trial that missed its primary endpoint overall.
A real subgroup signal
A defined sub-population with a statistically credible, clinically meaningful treatment effect.
A recognized FDA path
FDA feedback, or a defensible path to feedback, indicating a smaller confirmatory trial could support approval.
A genuine funding gap
A company without a realistic, non-dilutive path to fund the confirmatory trial on its own.
Current pipeline snapshot
Sourced from an ongoing screen of the distressed-biotech universe, AllianceXPartners is currently diligencing a shortlist of candidate programs spanning oncology, central nervous system, autoimmune and rare disease indications — each screened against the criteria above before any conversation with a prospective EAEU partner begins. Specific company names remain confidential during diligence and are disclosed only once a deal is signed and both parties agree to announce it.
Think your program fits?
If your company holds an asset that meets these criteria, or you represent an EAEU pharmaceutical partner looking to fund one, reach out for a confidential conversation.
AllianceXPartners 